Department of Gastrointestinal Endoscopy, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga #15. Col. Sección XVI. Del. Tlalpan., C.P. 14000, Mexico City, Mexico.
Instituto Nacional de Cancerología, Ciudad de México, Mexico.
Surg Endosc. 2019 Jul;33(7):2349-2356. doi: 10.1007/s00464-019-06719-9. Epub 2019 Feb 28.
Hemostatic powder (TC-325) is a new tool for treatment of gastrointestinal bleeding that allows the treatment of large surfaces with active bleeding. The aim was to describe the initial success of TC-325 for the control of GI bleeding.
We did a multicenter cohort study with patients admitted to the endoscopy service for GI bleeding. A format was generated to standardize the information obtained in each center. It was determined whether this treatment had been used as a single therapy or as a combination therapy. Descriptive statistics with medians and ranges, or averages with SD according to distribution.
Eighty-one patients with 104 endoscopic procedures were included. The median number of endoscopic procedures was 1 (1-3). In the first procedure, the initial success rate was 98.8% (n = 80), failure rate was 1.2% (n = 1), and rebleeding rate was 20% (n = 16). The majority of rebleeding cases occurred within the first 3 days (12/16, 75%). There was no association between rebleeding and etiology (malignant or benign; P = 0.6). In first procedure, 44 (54%) cases had monotherapy with TC-325 and 37 (46%) cases had a combined endoscopic therapy. There were no differences in initial success or rebleeding rates when TC-325 was used as monotherapy versus combined therapy (P = 0.7). The mortality rate was 4% (3/81).
TC-325 is effective for achieving initial control of bleeding in patients with different GI etiologies. The rate of bleeding recurrence is considerable in both patients with benign and malignant etiology.
止血粉（TC-325）是一种新的治疗胃肠道出血的工具，可用于治疗有活动性出血的大面积出血。目的是描述 TC-325 用于控制胃肠道出血的初始效果。
我们进行了一项多中心队列研究，纳入因胃肠道出血而接受内镜治疗的患者。制定了一种格式来标准化每个中心获得的信息。确定该治疗是作为单一疗法还是联合疗法使用。根据分布情况，采用中位数和范围的描述性统计，或平均值和标准差的平均值。
共纳入 81 例患者，共进行了 104 次内镜检查。内镜检查的中位数为 1 次（1-3 次）。在首次操作中，初始成功率为 98.8%（n=80），失败率为 1.2%（n=1），再出血率为 20%（n=16）。大多数再出血发生在第 1 天内（12/16，75%）。再出血与病因（恶性或良性）无关（P=0.6）。在首次操作中，44 例（54%）患者单独使用 TC-325 治疗，37 例（46%）患者联合内镜治疗。单独使用 TC-325 与联合治疗的初始成功率或再出血率无差异（P=0.7）。死亡率为 4%（3/81）。
TC-325 可有效控制不同胃肠道病因患者的初始出血。良性和恶性病因患者的再出血率都相当高。
